TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer

Nature Genetics

Volumn 49, Issue 9, 2017, Pages 1336-1345

  Kron, Ken J ^a   Murison, Alexander ^a   Zhou, Stanley ^b   Huang, Vincent ^c   Yamaguchi, Takafumi N ^c   Shiah, Yu Jia ^c   Fraser, Michael ^a   Van Der Kwast, Theodorus ^d   Boutros, Paul C ^b,c,e   Bristow, Robert G ^a,b   Lupien, Mathieu ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HOMEOBOX B13 PROTEIN; MESSENGER RNA; MK 0752; NOTCH RECEPTOR; TMPRSS2 ERG FUSION PROTEIN; TRANSCRIPTION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG; ERG PROTEIN, HUMAN; FOXA1 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; HOXB13 PROTEIN, HUMAN; ONCOPROTEIN; SERINE PROTEINASE; TMPRSS2 PROTEIN, HUMAN; TMPRSS2-ERG FUSION PROTEIN, HUMAN; TRANSCRIPTION FACTOR ERG;

22RV1 CELL LINE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURGERY; CELL INVASION; CHROMATIN IMMUNOPRECIPITATION; CLUSTER OF REGULATORY ELEMENT; COHORT ANALYSIS; CONTROLLED STUDY; CRIS REGULATORY ELEMENT; CRISPR-CAS9 SYSTEM; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE LOCUS; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENETIC REGULATION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HUVEC CELL LINE; LNCAP CELL LINE; MALE; NOTCH SIGNALING; NUCLEOTIDE SEQUENCE; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATECTOMY; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUMOR INVASION; VCAP CELL LINE; WHOLE GENOME SEQUENCING; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; REGULATORY SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HOMEODOMAIN PROTEINS; HUMANS; MALE; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; RECEPTORS, NOTCH; REGULATORY SEQUENCES, NUCLEIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL REGULATOR ERG;

EID: 85028697775     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3930     Document Type: Article

References (78)

1. Siegel, R.L., Miller, K.D. & Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 66, 7-30 (2016).
2. Tomlins, S.A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005).
3. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163, 1011-1025 (2015).
4. Lin, B. et al. Prostate-localized and androgen-regulated expression of the membranebound serine protease TMPRSS2. Cancer Res. 59, 4180-4184 (1999).
5. Clinckemalie, L. et al. Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element. Mol. Endocrinol. 27, 2028-2040 (2013).
6. Perner, S. et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am. J. Surg. Pathol. 31, 882-888 (2007).
7. Cerveira, N. et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 8, 826-832 (2006).
8. Carver, B.S. et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 41, 619-624 (2009).
9. King, J.C. et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 41, 524-526 (2009).
10. Mounir, Z. et al. TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation. Oncogene 34, 3815-3825 (2015).
11. Tomlins, S.A. et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10, 177-188 (2008).
12. Baltzinger, M., Mager-Heckel, A.M. & Remy, P. Xl erg: expression pattern and overexpression during development plead for a role in endothelial cell differentiation. Dev. Dyn. 216, 420-433 (1999).
13. Scott, E.W., Simon, M.C., Anastasi, J. & Singh, H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 265, 1573-1577 (1994).
14. Yang, H. et al. ETS family transcriptional regulators drive chromatin dynamics and malignancy in squamous cell carcinomas. eLife 4, e10870 (2015).
15. Nikolova-Krstevski, V. et al. ERG is required for the differentiation of embryonic stem cells along the endothelial lineage. BMC Dev. Biol. 9, 72 (2009).
16. Loughran, S.J. et al. The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nat. Immunol. 9, 810-819 (2008).
17. Meadows, S.M., Salanga, M.C. & Krieg, P.A. Kruppel-like factor 2 cooperates with the ETS family protein ERG to activate Flk1 expression during vascular development. Development 136, 1115-1125 (2009).
18. Wilson, N.K. et al. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell 7, 532-544 (2010).
19. Chen, Y. et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat. Med. 19, 1023-1029 (2013).
20. Yu, J. et al. An integrated network of androgen receptor, Polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17, 443-454 (2010).
21. Cai, C. et al. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J. Clin. Invest. 123, 1109-1122 (2013).
22. Pomerantz, M.M. et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat. Genet. 47, 1346-1351 (2015).
23. Moorman, C. et al. Hotspots of transcription factor colocalization in the genome of Drosophila melanogaster. Proc. Natl. Acad. Sci. USA 103, 12027-12032 (2006).
24. Gaulton, K.J. et al. A map of open chromatin in human pancreatic islets. Nat. Genet. 42, 255-259 (2010).
25. Song, L. et al. Open chromatin defined by DNaseI and FAIRE identifies regulatory elements that shape cell-type identity. Genome Res. 21, 1757-1767 (2011).
26. Whyte, W.A. et al. Master transcription factors and Mediator establish superenhancers at key cell identity genes. Cell 153, 307-319 (2013).
27. Parker, S.C.J. et al. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. Proc. Natl. Acad. Sci. USA 110, 17921-17926 (2013).
28. Akhtar-Zaidi, B. et al. Epigenomic enhancer profiling defines a signature of colon cancer. Science 336, 736-739 (2012).
29. Aran, D. & Hellman, A. DNA methylation of transcriptional enhancers and cancer predisposition. Cell 154, 11-13 (2013).
30. Aran, D., Sabato, S. & Hellman, A. DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes. Genome Biol. 14, R21 (2013).
31. Jia, L. et al. Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet. 5, e1000597 (2009).
32. Magnani, L. et al. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc. Natl. Acad. Sci. USA 110, E1490-E1499 (2013).
33. Stergachis, A.B. et al. Developmental fate and cellular maturity encoded in human regulatory DNA landscapes. Cell 154, 888-903 (2013).
34. Heintzman, N.D. et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459, 108-112 (2009).
35. Fraser, M. et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature 541, 359-364 (2017).
36. Taylor, G.C.A., Eskeland, R., Hekimoglu-Balkan, B., Pradeepa, M.M. & Bickmore, W.A. H4K16 acetylation marks active genes and enhancers of embryonic stem cells, but does not alter chromatin compaction. Genome Res. 23, 2053-2065 (2013).
37. Thurman, R.E. et al. The accessible chromatin landscape of the human genome. Nature 489, 75-82 (2012).
38. Koch, C.M. et al. The landscape of histone modifications across 1% of the human genome in five human cell lines. Genome Res. 17, 691-707 (2007).
39. Taylor, B.S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).
40. Lupien, M. et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132, 958-970 (2008).
41. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576-589 (2010).
42. Sérandour, A.A. et al. Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers. Genome Res. 21, 555-565 (2011).
43. Creyghton, M.P. et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci. USA 107, 21931-21936 (2010).
44. Lin, C.Y. et al. Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature 530, 57-62 (2016).
45. Gao, N. et al. The role of hepatocyte nuclear factor-3α (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol. Endocrinol. 17, 1484-1507 (2003).
46. Lupien, M. & Brown, M. Cistromics of hormone-dependent cancer. Endocr. Relat. Cancer 16, 381-389 (2009).
47. Economides, K.D. & Capecchi, M.R. Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development 130, 2061-2069 (2003).
48. Chang, H. et al. Synergistic action of master transcription factors controls epithelialto-mesenchymal transition. Nucleic Acids Res. 44, 2514-2527 (2016).
49. Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934-947 (2013).
50. Zhang, X. et al. Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nat. Genet. 48, 176-182 (2016).
51. Ooi, W.F. et al. Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity. Nat. Commun. 7, 12983 (2016).
52. Gao, N. et al. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development 132, 3431-3443 (2005).
53. Bhatia-Gaur, R. et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 13, 966-977 (1999).
54. Chen, R. et al. Cav1.3 channel α1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers. Urol. Oncol. 32, 524-536 (2014).
55. Jin, Y. et al. STAMP2 increases oxidative stress and is critical for prostate cancer. EMBO Mol. Med. 7, 315-331 (2015).
56. Weier, C. et al. Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer. J. Pathol. 230, 174-183 (2013).
57. Hay, D. et al. Genetic dissection of the α-globin super-enhancer in vivo. Nat. Genet. 48, 895-903 (2016).
58. Hollenhorst, P.C., Jones, D.A. & Graves, B.J. Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res. 32, 5693-5702 (2004).
59. McLean, C.Y. et al. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 28, 495-501 (2010).
60. Cowley, G.S. et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci. Data 1, 140035 (2014).
61. Klezovitch, O. et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc. Natl. Acad. Sci. USA 105, 2105-2110 (2008).
62. Wang, Q. et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell 27, 380-392 (2007).
63. Thangapazham, R. et al. Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer. BMC Cancer 14, 16 (2014).
64. Mansour, M.R. et al. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346, 1373-1377 (2014).
65. Affer, M. et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia 28, 1725-1735 (2014).
66. Berger, M.F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214-220 (2011).
67. Ciriello, G. et al. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127-1133 (2013).
68. Rickman, D.S. et al. Oncogene-mediated alterations in chromatin conformation. Proc. Natl. Acad. Sci. USA 109, 9083-9088 (2012).
69. Zhang, Y. et al. Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int. J. Cancer 119, 2071-2077 (2006).
70. Wang, Z. et al. Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-κB signaling pathways. J. Cell. Biochem. 109, 726-736 (2010).
71. Bin Hafeez, B. et al. Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin. Cancer Res. 15, 452-459 (2009).
72. Smyth, G.K. in Bioinformatics and Computational Biology Solutions Using R and Bioconductor (eds. Gentleman, R., Carey, V.J., Huber, W., Irizarry, R.A. & Dudoit, S.) 397-420 (Springer, 2005).
73. Wang, D. et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474, 390-394 (2011).
74. Takayama, K. et al. RUNX1, an androgen-and EZH2-regulated gene, has differential roles in AR-dependent and-independent prostate cancer. Oncotarget 6, 2263-2276 (2015).
75. Toropainen, S. et al. SUMO ligase PIAS1 functions as a target gene selective androgen receptor coregulator on prostate cancer cell chromatin. Nucleic Acids Res. 43, 848-861 (2015).
76. Asangani, I.A. et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278-282 (2014).
77. Huang, Q. et al. A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding. Nat. Genet. 46, 126-135 (2014).
78. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74 (2012).